ALKS Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Alkermes Plc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 24.21 USD 1.47%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast ALKS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALKS is 36.26 USD with a low forecast of 23.23 USD and a high forecast of 52.5 USD.

ALKS Lowest Forecast

Wall Street Target

ALKS Average Forecast

Wall Street Target

ALKS Highest Forecast

Wall Street Target

4% Downside

50% Upside

117% Upside

The latest public price target was made on Apr 10, 2024 by Akash Tewari from Jefferies , who expects ALKS stock to rise by 107% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Akash Tewari Jefferies	50 USD Upside 107%	3 weeks ago Apr 10, 2024	Alkermes (ALKS) PT Raised to $50 at Jefferies StreetInsider
Vamil Divan Mizuho Securities	35 USD Upside 45%	3 weeks ago Apr 9, 2024	Mizuho on Alkermes (ALKS): 'We maintain our Buy rating, believing that ALKS 2680 is underappreciated' StreetInsider
Akash Tewari Jefferies	25 USD Upside 3%	3 weeks ago Apr 9, 2024	Alkermes price target raised to $50 at Jefferies after 'excellent' NT2 data TheFly
Joel Beatty Robert W. Baird	37 USD Upside 53%	1 month ago Mar 18, 2024	Baird Starts Alkermes (ALKS) at Outperform StreetInsider

Price Target	50 USD
Upside/Downside	107%

Price Target	35 USD
Upside/Downside	45%

Price Target	25 USD
Upside/Downside	3%

Price Target	37 USD
Upside/Downside	53%

Shanghai Haohai Biological Technology Co Ltd

35% Upside

Legend Biotech Corp

91% Upside

Beijing Leadman Biochemistry Co Ltd

264% Upside

Inhibrx Inc

6% Upside

Shanghai Haohai Biological Technology Co Ltd

35% Upside

Legend Biotech Corp

91% Upside

Beijing Leadman Biochemistry Co Ltd

264% Upside

Inhibrx Inc

6% Upside

Yantai Zhenghai Bio-Tech Co Ltd

41% Upside

Surrozen Inc

233% Upside

Cell Biotech Co Ltd

364% Upside

Rallybio Corp

585% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Alkermes Plc's revenue is 13%. The projected CAGR for the next 3 years is -2%.

13%

-2%

-1%

What are analyst estimates?

Operating Income
Forecast

The compound annual growth rate of Alkermes Plc's operating income for the next 3 years is 6%.

N/A

6%

4%

What are analyst estimates?

Net Income
Forecast

The compound annual growth rate of Alkermes Plc's net income for the next 3 years is 10%.

N/A

10%

N/A

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for ALKS is 36.26 USD with a low forecast of 23.23 USD and a high forecast of 52.5 USD.

For the last 8 years the compound annual growth rate for Alkermes Plc's revenue is 13%. The projected CAGR for the next 3 years is -2%.

The compound annual growth rate of Alkermes Plc's operating income for the next 3 years is 6%.

The compound annual growth rate of Alkermes Plc's net income for the next 3 years is 10%.

Join more than 133,800+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.